Thymosin Alpha-1 – 5MG/10MG
$69.00 – $120.00
Discount per Quantity
| Quantity | Discount | Price |
|---|---|---|
| 5 - 8 | 5% | $65.55 – $114.00 |
| 9 + | 10% | $62.10 – $108.00 |
Thymosin Alpha-1
Thymosin Alpha-1 peptide, or Thymosin Alpha, TA1 or T α 1 is a protein fragment that is under heavy experimentation for its implications in the immune system. Some researches have suggested that it helps in the generation of T-cells to inhibit infection and bacterial dissemination.
Thymosin Alpha-1 is a ubiquitous endogenous polypeptide research has suggested that may be able to improve deficient and weakened immune systems. Thymosin Alpha-1 is one of the polypeptides of Thymosin Fraction 5, a crude extract of thymus gland.
Thymalfasin is the name given by researchers to a synthetically developed form of Thymosin Alpha-1, which has also been studied since its discovery. Thymalfasin: Thymalfasin contains 28 amino acids which are the active site similar to the naturally occurring Tα1 derived from a longer polypeptide precursor composed of 113 amino acids known as Prothymosin Alpha.
Thymosin Alpha-1 was first researched to understand and assess the immunomodulating ability of the peptide. Indeed researches demonstrated the ability of this peptide to enhance major histocompatibility complex (MHC) class I molecules, and increased cytokine production may result in strengthening immune responses.
As for potential actions of Thymosin Alpha-1, researchers suggest a number of ways that it may work by acting on the T-helper cells and cytotoxic T-cell populations. Tα 1, may stimulate differentiation of the T-cells (thymocytes) and terminal differentiation of the blood lymphocytes. Hence scientists even speculate that it might increase the generation of natural killer cells and eventually trigger cytokine mediated inflammation. In addition, the peptide has been examined for its properties to ameliorate macrophage activity as well as act as an alpha thrombin activity modifier.
Levels of natural killer (NK) and lymphokine activated killer cells (LAK) were measured in 11 patients with a variety of immune system abnormalities in this clinical study. The mean LAK-cell activity was approximately half that of control subjects, and these were immunodeficient subjects. When Thymosin Alpha-1 was given to the test subjects, researchers found that it did not increase NK or LAK cells significantly Three test subjects were noted as having an increase in LAK-cell activity of 30% while this was not statistically significant for the others.
Essentially, in this study, the production of reactive oxygen species (ROS) were observed in test models after expressing Tα 1. During this research Thymosin Alpha-1 was introduced in mice, that were given liver carcinoma. In this study, we isolated the leukomonocytes and HepG2 cells given the peptide from mouse spleens. Upon further analysis, these authors observed that the ROS level was significantly increased in the isolated leuko-monocytes but reduced in HepG2 cells. Meanwhile the peptide seemed to stimulate maybe leukomonocytes expression, and might have stalled cell cycle of HepG2 cells in this way to reduced their levels in the system.
THE CONTENT ON THIS WEBSITE IS STRICTLY INFORMATIONAL. IT IS NOT INTENDED TO BE TAKEN AS MEDICAL ADVICE OR AS A SCIENTIFIC PUBLICATION.
None of the products have been evaluated by The Food and Drug Administration, and are not for medical use. Their use in human or animal subjects is strictly prohibited by law, and they are available here only for in-vitro research purposes, by licensed professionals. By purchasing from this site, you agree to comply with our Terms and Conditions.
